StockData
Tarsus Pharmaceuticals, Inc. logo

Tarsus Pharmaceuticals, Inc. (TARS) stock

TARSNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 3, 2026Score 10/304% above fair value
$75.95−2.25 (-2.88%)

Close on Nov 18, 2026Market cap $3.33BP/E –Yield 0.00%

Tarsus Pharmaceuticals revenue

Revenue is the money a company takes in from selling its products and services, before any costs are deducted.

Tarsus Pharmaceuticals's revenue for the twelve months ending Jun 30, 2026 was $606.33M, up 105.2% year over year. For fiscal 2025 it was $451.36M, up 146.7% from the year before. The highest annual figure on record is $451.36M in fiscal 2025.

Annual revenue

PeriodPeriod endValueChange
FY2025Dec 31, 2025$451.36M+146.7%
FY2024Dec 31, 2024$182.95M+948.6%
FY2023Dec 31, 2023$17.45M-32.4%
FY2022Dec 31, 2022$25.82M-54.7%
FY2021Dec 31, 2021$57.03M–
FY2020Dec 31, 2020$0–

Quarterly revenue

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026$173.91M+69.4%
Q1 FY2026Mar 31, 2026$162.05M+106.9%
Q4 FY2025Dec 31, 2025$151.67M+128.4%
Q3 FY2025Sep 30, 2025$118.70M+146.7%
Q2 FY2025Jun 30, 2025$102.66M+151.5%
Q1 FY2025Mar 31, 2025$78.34M+183.7%
Q4 FY2024Dec 31, 2024$66.41M+407.9%
Q3 FY2024Sep 30, 2024$48.12M+2471.8%
Q2 FY2024Jun 30, 2024$40.81M–
Q1 FY2024Mar 31, 2024$27.61M+1004.6%
Q4 FY2023Dec 31, 2023$13.08M+30.8%
Q3 FY2023Sep 30, 2023$1.87M–
Q2 FY2023Jun 30, 2023$0-100.0%
Q1 FY2023Mar 31, 2023$2.50M+363.8%
Q4 FY2022Dec 31, 2022$10.00M+2858.6%
Q3 FY2022Sep 30, 2022$0-100.0%
Q2 FY2022Jun 30, 2022$15.28M-30.6%
Q1 FY2022Mar 31, 2022$539.00K-98.4%
Q4 FY2021Dec 31, 2021$338.00K–
Q3 FY2021Sep 30, 2021$1.24M–
Q2 FY2021Jun 30, 2021$22.02M–
Q1 FY2021Mar 31, 2021$33.43M–
Q4 FY2020Dec 31, 2020$0–
Q3 FY2020Sep 30, 2020$0–
Q2 FY2020Jun 30, 2020$0–
Q1 FY2020Mar 31, 2020$0–

More Tarsus Pharmaceuticals figures

See a number that looks wrong?